vs
Side-by-side financial comparison of ARROW FINANCIAL CORP (AROW) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
ARROW FINANCIAL CORP is the larger business by last-quarter revenue ($35.0M vs $18.7M, roughly 1.9× CytomX Therapeutics, Inc.). ARROW FINANCIAL CORP runs the higher net margin — 24.6% vs -0.8%, a 25.4% gap on every dollar of revenue. On growth, ARROW FINANCIAL CORP posted the faster year-over-year revenue change (7.1% vs -25.7%). ARROW FINANCIAL CORP produced more free cash flow last quarter ($7.5M vs $-15.8M). Over the past eight quarters, ARROW FINANCIAL CORP's revenue compounded faster (6.4% CAGR vs -15.9%).
Flagstar Bank, N.A. (FLG), is an American regional financial services holding company headquartered in Hicksville, New York. In 2023, the bank operated 395 branches However, they rebranded all of these under the Flagstar name on February 21, 2024.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
AROW vs CTMX — Head-to-Head
Income Statement — Q2 FY2024 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.0M | $18.7M |
| Net Profit | $8.6M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | — | -6.9% |
| Net Margin | 24.6% | -0.8% |
| Revenue YoY | 7.1% | -25.7% |
| Net Profit YoY | 42.3% | 97.6% |
| EPS (diluted) | $0.52 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $18.7M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | $35.0M | $25.1M | ||
| Q1 24 | $34.3M | $41.5M | ||
| Q4 23 | $25.6M | $26.6M | ||
| Q3 23 | $25.4M | $26.4M |
| Q2 25 | — | $-154.0K | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | $8.6M | $-6.5M | ||
| Q1 24 | $7.7M | $13.8M | ||
| Q4 23 | $7.7M | $837.0K | ||
| Q3 23 | $7.7M | $3.0M |
| Q2 25 | — | -6.9% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | — | -33.7% | ||
| Q1 24 | — | 28.1% | ||
| Q4 23 | — | -2.3% | ||
| Q3 23 | — | 11.8% |
| Q2 25 | — | -0.8% | ||
| Q1 25 | — | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | 24.6% | -26.0% | ||
| Q1 24 | 22.3% | 33.3% | ||
| Q4 23 | 30.2% | 3.1% | ||
| Q3 23 | 30.5% | 11.3% |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0.52 | — | ||
| Q1 24 | $0.45 | — | ||
| Q4 23 | $0.46 | — | ||
| Q3 23 | $0.46 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $383.0M | $119.9M |
| Total Assets | $4.2B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | — | $43.2M | ||
| Q1 24 | — | $36.2M | ||
| Q4 23 | — | $17.2M | ||
| Q3 23 | — | $26.0M |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $6.5M | — | ||
| Q3 23 | — | — |
| Q2 25 | — | $119.9M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $-456.0K | ||
| Q3 24 | — | $-23.5M | ||
| Q2 24 | $383.0M | $-31.2M | ||
| Q1 24 | $378.0M | $-31.7M | ||
| Q4 23 | $379.8M | $-47.4M | ||
| Q3 23 | $360.0M | $-51.2M |
| Q2 25 | — | $175.1M | ||
| Q1 25 | — | $98.5M | ||
| Q4 24 | — | $120.5M | ||
| Q3 24 | — | $139.0M | ||
| Q2 24 | $4.2B | $159.2M | ||
| Q1 24 | $4.3B | $184.7M | ||
| Q4 23 | $4.2B | $201.8M | ||
| Q3 23 | $4.3B | $221.2M |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.02× | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.1M | $-15.8M |
| Free Cash FlowOCF − Capex | $7.5M | $-15.8M |
| FCF MarginFCF / Revenue | 21.5% | -84.6% |
| Capex IntensityCapex / Revenue | 4.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.06× | — |
| TTM Free Cash FlowTrailing 4 quarters | $9.6M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.0M | ||
| Q4 24 | — | $-19.9M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | $9.1M | $-19.5M | ||
| Q1 24 | $10.3M | $-26.0M | ||
| Q4 23 | $-16.3M | $-22.0M | ||
| Q3 23 | $11.2M | $-18.2M |
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | $7.5M | $-19.6M | ||
| Q1 24 | $9.2M | $-26.2M | ||
| Q4 23 | $-16.9M | $-22.2M | ||
| Q3 23 | $9.8M | $-18.3M |
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | 21.5% | -78.2% | ||
| Q1 24 | 26.8% | -63.1% | ||
| Q4 23 | -66.1% | -83.5% | ||
| Q3 23 | 38.6% | -69.2% |
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 4.5% | 0.4% | ||
| Q1 24 | 3.4% | 0.3% | ||
| Q4 23 | 2.4% | 1.0% | ||
| Q3 23 | 5.6% | 0.0% |
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.35× | -1.89× | ||
| Q4 23 | -2.11× | -26.24× | ||
| Q3 23 | 1.45× | -6.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AROW
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
